genedrive (GDR) Competitors

genedrive logo
GBX 0.84 -0.07 (-7.22%)
As of 11/20/2026 12:25 PM Eastern

GDR vs. ABDX, YGEN, VRCI, AGL, and PRM

Should you buy genedrive stock or one of its competitors? genedrive's main competitors and comparable companies include Abingdon Health (ABDX), Yourgene Health (YGEN), Verici Dx (VRCI), ANGLE (AGL), and Proteome Sciences (PRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does genedrive compare to Abingdon Health?

genedrive (LON:GDR) and Abingdon Health (LON:ABDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

0.1% of genedrive shares are held by institutional investors. Comparatively, 0.8% of Abingdon Health shares are held by institutional investors. 28.1% of genedrive shares are held by insiders. Comparatively, 5.4% of Abingdon Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Abingdon Health has a net margin of -19.36% compared to genedrive's net margin of -500.75%. Abingdon Health's return on equity of -34.31% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
genedrive-500.75% -1,044.57% -74.09%
Abingdon Health -19.36%-34.31%-17.93%

Abingdon Health has higher revenue and earnings than genedrive. Abingdon Health is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
genedrive£929K14.43-£21.22M-£0.79N/A
Abingdon Health£10.99M3.30-£796.37K-£0.51N/A

genedrive has a beta of 1.004, suggesting that its share price is 0% more volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.132, suggesting that its share price is 87% less volatile than the broader market.

In the previous week, genedrive had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Abingdon Health. genedrive's average media sentiment score of 0.67 beat Abingdon Health's score of 0.00 indicating that genedrive is being referred to more favorably in the media.

Company Overall Sentiment
genedrive Positive
Abingdon Health Neutral

Summary

Abingdon Health beats genedrive on 7 of the 13 factors compared between the two stocks.

How does genedrive compare to Yourgene Health?

Yourgene Health (LON:YGEN) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, genedrive has a beta of 1.004, indicating that its stock price is 0% more volatile than the broader market.

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 28.1% of genedrive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, genedrive had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Yourgene Health. genedrive's average media sentiment score of 0.67 beat Yourgene Health's score of 0.00 indicating that genedrive is being referred to more favorably in the news media.

Company Overall Sentiment
Yourgene Health Neutral
genedrive Positive

Yourgene Health has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A
genedrive£929K14.43-£21.22M-£0.79N/A

Yourgene Health has a net margin of -27.55% compared to genedrive's net margin of -500.75%. Yourgene Health's return on equity of -27.06% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
Yourgene Health-27.55% -27.06% -6.71%
genedrive -500.75%-1,044.57%-74.09%

Summary

Yourgene Health beats genedrive on 8 of the 12 factors compared between the two stocks.

How does genedrive compare to Verici Dx?

Verici Dx (LON:VRCI) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Verici Dx has a beta of 1.222, indicating that its share price is 22% more volatile than the broader market. Comparatively, genedrive has a beta of 1.004, indicating that its share price is 0% more volatile than the broader market.

In the previous week, genedrive had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Verici Dx. genedrive's average media sentiment score of 0.67 beat Verici Dx's score of 0.00 indicating that genedrive is being referred to more favorably in the news media.

Company Overall Sentiment
Verici Dx Neutral
genedrive Positive

9.9% of Verici Dx shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 1.1% of Verici Dx shares are held by company insiders. Comparatively, 28.1% of genedrive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Verici Dx has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.52M3.37-£6.56M£0.101.78
genedrive£929K14.43-£21.22M-£0.79N/A

Verici Dx has a net margin of -223.60% compared to genedrive's net margin of -500.75%. Verici Dx's return on equity of -127.57% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-223.60% -127.57% -26.14%
genedrive -500.75%-1,044.57%-74.09%

Summary

Verici Dx beats genedrive on 9 of the 13 factors compared between the two stocks.

How does genedrive compare to ANGLE?

ANGLE (LON:AGL) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

genedrive has lower revenue, but higher earnings than ANGLE. genedrive is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.62M2.89-£21.76M-£4.80N/A
genedrive£929K14.43-£21.22M-£0.79N/A

17.5% of ANGLE shares are owned by institutional investors. Comparatively, 0.1% of genedrive shares are owned by institutional investors. 2.7% of ANGLE shares are owned by insiders. Comparatively, 28.1% of genedrive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

genedrive has a net margin of -500.75% compared to ANGLE's net margin of -1,560.86%. ANGLE's return on equity of -157.49% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-1,560.86% -157.49% -29.89%
genedrive -500.75%-1,044.57%-74.09%

ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, genedrive has a beta of 1.004, meaning that its stock price is 0% more volatile than the broader market.

In the previous week, genedrive had 1 more articles in the media than ANGLE. MarketBeat recorded 1 mentions for genedrive and 0 mentions for ANGLE. genedrive's average media sentiment score of 0.67 beat ANGLE's score of 0.00 indicating that genedrive is being referred to more favorably in the news media.

Company Overall Sentiment
ANGLE Neutral
genedrive Positive

Summary

genedrive beats ANGLE on 8 of the 13 factors compared between the two stocks.

How does genedrive compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by company insiders. Comparatively, 28.1% of genedrive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Proteome Sciences has a net margin of -61.46% compared to genedrive's net margin of -500.75%. Proteome Sciences' return on equity of 23.85% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-61.46% 23.85% -19.25%
genedrive -500.75%-1,044.57%-74.09%

In the previous week, genedrive had 1 more articles in the media than Proteome Sciences. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Proteome Sciences. genedrive's average media sentiment score of 0.67 beat Proteome Sciences' score of 0.00 indicating that genedrive is being referred to more favorably in the news media.

Company Overall Sentiment
Proteome Sciences Neutral
genedrive Positive

Proteome Sciences has a beta of 0.157, meaning that its share price is 84% less volatile than the broader market. Comparatively, genedrive has a beta of 1.004, meaning that its share price is 0% more volatile than the broader market.

Proteome Sciences has higher revenue and earnings than genedrive. Proteome Sciences is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.77M0.97-£4.08M-£0.72N/A
genedrive£929K14.43-£21.22M-£0.79N/A

Summary

Proteome Sciences beats genedrive on 7 of the 13 factors compared between the two stocks.

Get genedrive News Delivered to You Automatically

Sign up to receive the latest news and ratings for GDR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GDR vs. The Competition

MetricgenedriveLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£13.41M£10.69B£7.78B£2.67B
Dividend Yield1.57%1.46%2.47%5.11%
P/E Ratio-1.0648.9233.2222.78
Price / Sales14.438.468.104.91
Price / Cash2.0026.5521.0120.23
Price / Book0.294.194.262.40
Net Income-£21.22M£56.66B£3.50B£5.88B
1 Month Performance-18.93%-7.81%-10.48%-4.75%
1 Year Performance-4.79%11.09%-4.61%5.15%

genedrive Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GDR
genedrive
N/AGBX 0.84
-7.2%
N/A-11.0%£13.41M£929KN/A43
ABDX
Abingdon Health
N/AGBX 9
+5.9%
N/A+19.0%£39.16M£10.99MN/A84
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
VRCI
Verici Dx
N/AGBX 0.20
-1.0%
N/A-73.7%£13.52M£3.52M2.0319
AGL
ANGLE
N/AGBX 2.35
-11.3%
N/A+0.0%£7.58M£2.62MN/A650

Related Companies and Tools


This page (LON:GDR) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners